Global Major Depressive Disorder (MDD) Treatment Market Set to Expand Saliently at a Robust CAGR during the Forecast Period 2018-2026


Posted October 23, 2018 by coherent3

Major depressive disorder (MDD) also known as clinical depression is a mental health disorder which affects mood, behavior as well as appetite and sleep.

 
Major depressive disorder (MDD) also known as clinical depression is a mental health disorder which affects mood, behavior as well as appetite and sleep. The exact cause of MDD is not known, however, several factors which can increase its risk is combination of genes and stress that affects brain chemistry and reduce the ability to maintain mood stability. Imbalanced hormone, alcohol or drug abuse, certain medical conditions such as cancer or hypothyroidism, and some adverse effects of medication such as steroids can also lead to MDD. Changing lifestyles such as work pressure, alcohol abuse, and others has resulted in increasing prevalence of MDD, which is expected to drive market growth over the forecast period. For instance, according to an article published in National Center for Biotechnology Information 2015, MDD is the most common psychiatric disorder in India and the lifetime prevalence of MDD is 10–25% for women, and 5–12% for men.

Download PDF Brochure of Research Report:
https://www.coherentmarketinsights.com/insight/request-pdf/1217

Major Depressive Disorder (MDD) Treatment Market Taxonomy
The major depressive disorder (MDD) treatment market is segmented on the basis of product type and geography
On the basis of product type, major depressive disorder (MDD) treatment market is segmented into:
• Drug Type
◦ Antidepressants
▪ Selective Serotonin Reuptake Inhibitors (SSRIS)
• Lexapro (Escitalopram)
• Viibryd (Vilazodone)
▪ Dopamine Norepinephrine Reuptake Inhibitor
▪ Serotonin Norepinephrine Reuptake Inhibitor
• Cymbalta (Duloxetine)
• Effexor (Venlafaxine)
• Fetzima (Levomilnacipran)
• Savella (Milnacipran)
• Pristiq (Desvenlafaxine)
▪ Serotonin Modulators
▪ Norepinephrine-Serotonin Modulator
▪ Tricyclics and Tetracyclics
◦ Atypical Antidepressants
◦ Antipsychotics
▪ Abilify (Aripiprazole)
▪ Seroquel XR (Quetiapine XR)
▪ Rexulti (Brexpiprazole)
◦ Neuromodulators
◦ Stem Cell Therapy

Request Customization:
https://www.coherentmarketinsights.com/insight/request-customization/1217

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By coherent
Country Bangladesh
Categories Fitness , Health
Tags global major depressive disorder mdd treatment market analysis , global major depressive disorder mdd treatment market growth , global major depressive disorder mdd treatment market share
Last Updated October 23, 2018